Immunotherapies Open New Avenues in Relapsed/Refractory ALL

The 5-year survival rate for relapsed/refractory acute lymphoblastic leukemia has been below 10%. Immunotherapies, however, are starting to challenge that paradigm.

Source: CancerNetwork - October 3, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma Conferences/NCCN 2016 Source Type: news